Pharmacogenetics Newsletter Archives
Released Issues
2011; Volume 3
Issue 47: Question: Can metoprolol lower the pulse effectively in patients who are known ultra-rapid metabolizers of CYP2D6?
Issue 39: Question: How can the efficacy of riluzole (Rilutek) be affected for the treatment of amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) in patients with the genetic polymorphism, CYP1A2*1F?
Issue 35: Question: Are CYP2D6 poor metabolizers at greater risk for bradycardia and/or hypotension when taking the beta-receptor blocker, metoprolol (Lopressor, Toprol, Toprol XL)?
Issue 31: Question: Do patients with genetic polymorphism to CYP2C19 have different antacid effects and eradication rates of H. pylori while taking lansoprazole (Prevacid)?
Issue 27: Question: Why are patients with genetic polymorphisms to CYP2D6 more likely to have weight loss and tachycardia while taking atomoxetine (Strattera)?
Issue 23: Question: What genetic polymorphisms of the CYP3A4 enzyme have the potential to influence drug efficacy and/or safety?
Issue 19: Question: Why are certain words in the pharmacogenetic literature and Pharmacology Weekly newsletters italicized?
Issue 15: Question: What genetic polymorphism has been associated with the risk of developing polydipsia induced hyponatremia in patients with schizophrenia taking risperidone (Risperdal)?
Issue 11: Question: Why are rheumatoid arthritis patients with CYP1A2*1F genetic polymorphism at an increased risk for leflunomide (Arava) toxicity?
Issue 7: Question: What are common medications that may be impacted by known genetic polymorphisms of CYP1A2 enzyme?
Issue 3: Question: What common genetic polymorphisms of the CYP1A2 enzyme have the potential to influence drug efficacy and/or safety?
2010; Volume 2
Issue 47: Question: What medications used in clinical practice are likely to be influenced by the presence of genetic polymorphisms to CYP2D6?
Issue 43: Question: What are common genetic polymorphisms to cytochrome P450 (CYP) 2D6 that could impact drug metabolism?
Issue 39: Question: What are some common medications that are known to be influenced by the activity of the enzyme, thiopurine methyltransferase (TPMT)?
Issue 35: Question: What are common genetic polymorphisms to thiopurine methyltransferase (TPMT) that could impact drug metabolism?
Issue 31: Question: Why are patients with genetic defects to the genes for transferrin receptor-2 (Tfr2) and ferroportin 1 at an increased risk for developing iron toxicity or hemochromatosis with iron supplements?
Issue 27: Question: Why are patients with genetic defects to the hepcidin antimicrobial peptide (HAMP) gene at an increased risk for developing iron toxicity or hemochromatosis with iron supplements?
Issue 23: Question: Why are patients with genetic defects to the hemojuvelin (HJV) gene at an increased risk for developing iron toxicity or hemochromatosis?
Issue 19: Question: What is the mechanism by which iron supplements can cause significant toxicity in patients with genetic polymorphisms to the HFE gene?
Issue 15: Question: What genetic defects can predispose patients receiving iron (Fe) supplements to develop hemochromatosis (iron overload)?
Issue 11: Question: What common genetic polymorphisms to vitamin K 2,3-epoxide reductase complex 1 (VKORC1) are known to influence the pharmacologic properties of warfarin (Coumadin, Jantoven)?
Issue 7: Question: Why should patients of Asian descent receive human leukocyte antigen (HLA)-B genetic testing before being prescribed carbamazepine (Carbatrol; Equetro; Tegretol)?
Issue 3: Question: What are the common genetic polymorphisms to cytochrome P450 (CYP) 2C19 that could impact drug metabolism?
2009; Volume 1
Issue 12: Question: What are some common genetic risk factors that put women at risk for developing venous thromboembolism (DVT and/or pulmonary embolism) when taking oral contraceptives (birth control pills)?
Issue 11: Question: What are some common lab tests or techniques used for determining single nucleotide genetic polymorphisms (SNPs) that can facilitate patient specific drug therapy?
Issue 10: Question: How do you interpret a single nucleotide polymorphism (SNPs) when reported in the medical literature? (ex. What does CYP2C19*3 mean and does it relate to its SNP, W212X (G636A)?)
Issue 9: Question: What are good online pharmacogenetic resources that clinicians should be aware of?
Issue 8: Question: How do known genetic polymorphisms to VKORC1 influence the safety and efficacy of warfarin (Coumadin®, Jantoven®)?
Issue 7: Question: What influences do genetic polymorphisms to cytochrome P-450 (CYP) 2C19 have on cardiovascular disease (CVD) outcomes in patients taking clopidogrel (Plavix®)?
Issue 6: Question: What is a single nucleotide polymorphism (SNP) and how does it impact drug therapy?
Issue 5: Question: How do oral contraceptives (birth control pills) increase the risk of clots or venous thromboembolisms (DVTs and pulmonary embolisms) in patients with the genetic polymorphism, Factor V Leiden?
Issue 4: Question: How do genetic polymorphisms to UGT1A1*28 increase the risk for life-threatening neutropenia when receiving irinotecan (Camptosar®)?
Issue 3: Question: How does a patient's genetics predispose them to abacavir (Ziagen®) induced hypersensitivity reaction that prevents future use of the drug for the treatment of HIV infection?
Issue 2: Question: How is warfarin (Coumadin®, Jantoven®) use in clinical practice influenced by known genetic polymorphisms to CYP450 2C9 and when is testing needed, if at all?
Issue 1: Question: What is pharmacogenetics and why should healthcare providers seek to understand it?
Share
